{
    "clinical_study": {
        "@rank": "163302", 
        "arm_group": {
            "arm_group_label": "High Dose Conditioning", 
            "arm_group_type": "Experimental", 
            "description": "Single arm - receives high dose Etoposide phosphate, Ifosfamide, and Carboplatin followed by Autologous Stem Cell Transplantation"
        }, 
        "brief_summary": {
            "textblock": "This is a pilot study to evaluate the response rates for patients undergoing high dose\n      conditioning chemotherapy using Etoposide, Carboplatin and Ifosfamide followed by autologous\n      stem cell transplantation for the treatment of recurrent Nasopharyngeal Cancer (NPC) in\n      children, adolescents, and young adults."
        }, 
        "brief_title": "Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma", 
        "completion_date": {
            "#text": "May 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Recurrent Nasopharynx Carcinoma", 
        "condition_browse": {
            "mesh_term": [
                "Carcinoma", 
                "Nasopharyngeal Neoplasms"
            ]
        }, 
        "detailed_description": {
            "textblock": "The use of high dose chemotherapy followed by autologous peripheral blood stem cell (PBSC)\n      transplantation in recurrent nasopharyngeal carcinoma has shown promise when compared with\n      standard chemotherapy. This study has been designed to evaluate response rates and\n      toxicities associated with undergoing high dose conditioning with Etoposide, Carboplatin and\n      Ifosfamide followed by autologous stem cell transplantation support in the treatment of\n      recurrent nasopharyngeal carcinoma in children, adolescents, and young adults."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Imaging and tissue diagnosis of recurrent or progressive nasopharyngeal carcinoma\n\n          -  Documentation of previous treatment including conventional chemotherapy and/or\n             radiation therapy as clinically appropriate\n\n          -  Ages 2 to 30 years of age\n\n          -  Negative serum pregnancy test if applicable\n\n          -  Calculated creatinine clearance of greater than 60 mL/minute, serum creatinine of\n             less than 12o micromoles/L, total bilirubin less than 2 mg/dL and aspartate\n             aminotransferase (AST) must be less than twice the upper limit of normal\n\n        Exclusion Criteria:\n\n          -  Unsuitable candidate for autologous transplantation due to comorbidities or\n             intractable psychosocial issues\n\n          -  Pregnancy\n\n          -  Breast-feeding women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "30 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "10", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 9, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02137096", 
            "org_study_id": "IRB201400316", 
            "secondary_id": "PEDS006"
        }, 
        "intervention": [
            {
                "arm_group_label": "High Dose Conditioning", 
                "description": "Etoposide is one of three drugs used in the high-dose conditioning phase", 
                "intervention_name": "Etoposide phosphate", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Etopophos", 
                    "Toposar"
                ]
            }, 
            {
                "arm_group_label": "High Dose Conditioning", 
                "description": "Carboplatin is one of the drugs used in the high-dose conditioning phase.", 
                "intervention_name": "Carboplatin", 
                "intervention_type": "Drug", 
                "other_name": "Paraplatin"
            }, 
            {
                "arm_group_label": "High Dose Conditioning", 
                "description": "Ifosfamide is one of the drugs used in the high-dose conditioning phase", 
                "intervention_name": "Ifosfamide", 
                "intervention_type": "Drug", 
                "other_name": "Ifex"
            }, 
            {
                "arm_group_label": "High Dose Conditioning", 
                "description": "Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.", 
                "intervention_name": "Autologous Stem Cell Transplantation", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Etoposide", 
                "Etoposide phosphate", 
                "Isophosphamide mustard", 
                "Ifosfamide", 
                "Carboplatin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": "Recurrent nasopharynx carcinoma", 
        "lastchanged_date": "May 12, 2014", 
        "location": {
            "contact": {
                "email": "lelderou@peds.ufl.edu", 
                "last_name": "Lamis Eldjerou, MD", 
                "phone": "352-273-9120"
            }, 
            "contact_backup": {
                "email": "slaytwb@peds.ufl.edu", 
                "last_name": "William Slayton, MD", 
                "phone": "352-273-9120"
            }, 
            "facility": {
                "address": {
                    "city": "Gainesville", 
                    "country": "United States", 
                    "state": "Florida", 
                    "zip": "32610"
                }, 
                "name": "UF Health Shands Hospital"
            }, 
            "investigator": {
                "last_name": "Lamis Eldjerou, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "High Dose Conditioning With Ifosfamide, Carboplatin, and Etoposide With Autologous Stem Cell Transplantation for Patients With Recurrent Nasopharyngeal Carcinoma", 
        "overall_contact": {
            "email": "leldjerou@peds.ufl.edu", 
            "last_name": "Lamis Eldjerou,, MD", 
            "phone": "352-273-9120"
        }, 
        "overall_contact_backup": {
            "email": "slaytwb@peds.ufl.edu", 
            "last_name": "William Slayton,, MD", 
            "phone": "352-273-9120"
        }, 
        "overall_official": {
            "affiliation": "University of Florida", 
            "last_name": "Lamis Elderou, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate the response rates for patients undergoing high dose conditioning using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent NPC in children, adolescents, and young adults.", 
            "measure": "Evaluate the tumor response", 
            "safety_issue": "No", 
            "time_frame": "12 months after completion of treatment"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02137096"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "To evaluate the toxicities associated with undergoing high dose conditioning using Etoposide, Carboplatin and Ifosfamide followed by autologous stem cell transplantation for the treatment of recurrent NPC in children, adolescents, and young adults", 
            "measure": "Treatment related Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "60 months after treatment"
        }, 
        "source": "University of Florida", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Florida", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}